 All patients with CML in any phase of the disease chronic, accelerated or blast phase that has received treatment with any FDA-approved tyrosine kinase inhibitor eg, imatinib, dasatinib, nilotinib not on an MDACC clinical trial regardless of prior treatment history that has had at least one clinic visit at MDACC will be eligible. 